As an initial indication, the company intends to submit an investigational new drug (IND) application seeking FDA permission to enter a Phase III clinical trial of Revimmune usage in bone marrow transplants to treat and possibly cure sickle cell anemia.
The technology is being licensed to Biovest for transplant rejection from Revimmune, LLC, a Hopkins Capital Group II portfolio company, which holds the exclusive license for the technology from the Johns Hopkins University. Revimmune, LLC, has previously licensed the exclusive, worldwide rights to Revimmune for treatment of all autoimmune diseases to Accentia Biopharmaceuticals.